KalVista Pharmaceuticals
Clinical trials sponsored by KalVista Pharmaceuticals, explained in plain language.
A pharmaceutical company developing oral therapies for hereditary angioedema and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Could a simple pill shield HAE patients from Procedure-Triggered attacks?
Disease control Recruiting nowThis trial tests whether the drug sebetralstat can prevent swelling attacks in people with hereditary angioedema (HAE) when taken before a medical procedure. Participants aged 12 and older with HAE type I or II will take sebetralstat just before their scheduled procedure. The mai…
Phase 4 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for kids with rare swelling disorder: early access drug offered
Disease control Expanded accessThis program provides early access to an investigational drug called sebetralstat for children aged 2 to 11 with hereditary angioedema (HAE), a condition causing sudden, painful swelling. The drug is taken at the start of an attack to reduce symptoms. It is available to children …
Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC